Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
Hunan Province Tumor Hospital
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
This study aims to explore the efficacy of Anlotinib with or without Immune Checkpoint Inhibitor in Standard Chemo-immunotherapy Failed Advanced NSCLC.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- acronym
- ATHENA
- status
- RECRUITING
- phase
- PHASE2, PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 1200
- sponsor
- Hunan Province Tumor Hospital
- conditions
- Non-small Cell Lung Cancer
- interventions
- DRUG: Anlotinib plus the same Immune Checkpoint Inhibitors.; DRUG: Anlotinib plus the new Immune Checkpoint Inhibitors.; DRUG: Anlotinib
- start date
- 2020-03-24
- start date type
- ACTUAL
- primary completion date
- 2028-03-24
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT04322617
- Published
- Mar 26, 2020
- Updated
- Jun 4, 2024
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT04322617
- Categories
- Non-small Cell Lung Cancer
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials